CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: February 17, 2016
Result type: Reports
Project Number: SR0481-000
Product Line: Reimbursement Review

Generic Name: Ixekizumab

Brand Name: Taltz

Manufacturer: Eli Lilly Canada Inc.

Therapeutic Area: Psoriasis, moderate to severe plaque

Indications: Psoriasis, moderate to severe plaque

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: October 25, 2016

Recommendation Type: Reimburse with clinical criteria and/or conditions